Zacks Investment Research cut shares of Kaleido Biosciences (NASDAQ:KLDO) from a hold rating to a sell rating in a research note issued to investors on Friday, Zacks.com reports.

According to Zacks, “Kaleido Biosciences Inc. is a clinical-stage healthcare company. It focuses on leveraging the potential of the microbiome organ to treat disease and improve human health. The Company’s product candidates are Microbiome Metabolic Therapies(TM), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes. Kaleido Biosciences Inc. is based in Lexington, Massachusetts. “

Several other research firms have also issued reports on KLDO. Chardan Capital initiated coverage on shares of Kaleido Biosciences in a research report on Tuesday, April 23rd. They set a buy rating and a $17.50 price target for the company. Morgan Stanley initiated coverage on shares of Kaleido Biosciences in a research report on Monday, March 25th. They set an overweight rating and a $17.00 price target for the company. Canaccord Genuity initiated coverage on shares of Kaleido Biosciences in a research report on Monday, March 25th. They set a buy rating and a $19.00 price target for the company. JPMorgan Chase & Co. initiated coverage on shares of Kaleido Biosciences in a research report on Monday, March 25th. They set a neutral rating and a $15.00 price target for the company. Finally, Goldman Sachs Group initiated coverage on shares of Kaleido Biosciences in a research report on Monday, March 25th. They set a buy rating and a $20.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $17.70.

Shares of NASDAQ:KLDO opened at $15.96 on Friday. Kaleido Biosciences has a 52-week low of $12.50 and a 52-week high of $19.00.

Kaleido Biosciences (NASDAQ:KLDO) last announced its earnings results on Thursday, May 2nd. The company reported ($1.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.89). Analysts forecast that Kaleido Biosciences will post -2.78 EPS for the current fiscal year.

Large investors have recently modified their holdings of the company. FMR LLC bought a new position in Kaleido Biosciences during the 1st quarter worth $25,143,000. BlueCrest Capital Management Ltd bought a new position in Kaleido Biosciences during the 1st quarter worth $165,000. Morgan Stanley bought a new position in Kaleido Biosciences during the 1st quarter worth $31,000. Arrowgrass Capital Partners US LP bought a new position in Kaleido Biosciences during the 1st quarter worth $725,000. Finally, Citigroup Inc. bought a new position in Kaleido Biosciences during the 1st quarter worth $35,000. 77.83% of the stock is owned by hedge funds and other institutional investors.

Kaleido Biosciences Company Profile

Kaleido BioSciences, Inc develops microbiome metabolic therapies. It offers treatment for hyperammonemia, a metabolic condition generally characterized by elevated levels of ammonia in the blood; infections caused by multi-drug resistant bacteria; chronic kidney disease; atherosclerotic cardiovascular disease; and drug or disease induced diarrhea.

Read More: Resistance Level

Get a free copy of the Zacks research report on Kaleido Biosciences (KLDO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Kaleido Biosciences (NASDAQ:KLDO)

Receive News & Ratings for Kaleido Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kaleido Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.